Colon Cancer Clinical Trial
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).
COLUMBIA-1 is a Phase 1b/2, open-label, multicenter, randomized, multidrug platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) in combination with novel oncology therapies in patients with first-line metastatic MSS-CRC. The study is designed to concurrently evaluate potential novel combinations with clinical promise using a 2-part approach. Part 1 is a Phase 1b study of safety, and Part 2 is a Phase 2 study of efficacy and safety.
Written informed consent and any locally required authorization obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations.
Age ≥ 18 years at the time of screening.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Subjects must have histologic documentation of advanced or metastatic CRC and: (a) A documented mutation test during screening and confirmed tumor locations from disease assessment for enrollment. (b) Subjects must NOT have defective DNA mismatch repair (MSI) as documented by testing. (c) Subjects must not have received any prior systemic therapy for recurrent/metastatic disease (prior adjuvant chemotherapy or radio-chemotherapy is acceptable so long as progression was not within 6 months of completing the adjuvant regimen).
Subjects must have at least one lesion that is measurable by RECIST v1.1 (Eisenhauer et al, 2009).
Subjects must have adequate organ function.
Subjects with medical conditions requiring systemic anticoagulation (eg, atrial fibrillation) are eligible provided that both of the following criteria are met: - The subject has an in-range INR on a stable dose of oral anticoagulant or be on a stable dose of low molecular weight heparin. - The subject has no active bleeding or pathological condition that carries a high risk of bleeding.
8 Body weight >35 kg. 9. Adequate method of contraception per protocol
History of allogeneic organ transplantation.
Active or prior documented autoimmune disorders within the past 5 years.
History of venous thrombosis within the past 3 months.
Cardiovascular criteria: (a) Presence of acute coronary syndrome including myocardial infarction or unstable angina pectoris, other arterial thrombotic event including cerebrovascular accident or transient ischemic attack or stroke within the past 6 months. (b) New York Heart Association (NYHA) class II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension. (c) History of hypertensive crisis/hypertensive encephalopathy within the past 6 months.
Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms.
No significant history of bleeding events or gastrointestinal perforation.
Uncontrolled intercurrent illness.
History of another primary malignancy except for: (a) Malignancy treated with curative intent and with no known active disease ≥ 5 years of low potential risk for recurrence. (b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. (c) Adequately treated carcinoma in situ without evidence of disease.
History of active primary immunodeficiency.
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Any unresolved toxicity NCI CTCAE Grade > 1 from previous anticancer therapy.
History of leptomeningeal disease or cord compression.
Untreated central nervous system (CNS) metastases.
Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
Known dihydropyrimidine dehydrogenase (DPD) deficiency.
Prior immunotherapy or anti-angiogenics.
Receipt of live attenuated vaccine within the past 30 days.
Major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days.
Current or prior use of immunosuppressive medication within the past 14 days, with exceptions per protocol.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 21 Locations for this study
Los Angeles California, 90095, United States
Sacramento California, 95817, United States
Ann Arbor Michigan, 48109, United States
Las Vegas Nevada, 89169, United States
New York New York, 10065, United States
Canton Ohio, 44718, United States
Providence Rhode Island, 02903, United States
Chattanooga Tennessee, 37404, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
Charlottesville Virginia, 22908, United States
Clayton , 3168, Australia
Heidelberg , 3084, Australia
Melbourne , 3000, Australia
Toronto Ontario, M5G 1, Canada
Nantes , 44000, France
Villejuif , 94805, France
Barcelona , 08035, Spain
Barcelona , 08916, Spain
Madrid , 28027, Spain
Madrid , 28046, Spain
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.